Company ProfilePremium

Analytica Limited

Company Profile Analysis

Ticker: ALT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Analytica Limited - Company showcase

Year Founded & Workforce

1985

Analytica Limited logo

Analytica Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Analytica Limited Overview

Analytica Limited was a Queensland micro-cap medical-device developer. For more than a decade it tried to commercialise the PeriCoach System, a connected pelvic-floor muscle trainer for women with stress urinary incontinence. PeriCoach combined an intravaginal sensor device, a smartphone app and a clinician web portal. The underlying exercise data was pooled in a cloud database the company described as the world's largest of its kind. The company also held a legacy infusion franchise: the AutoStart burette, later grouped with AutoFlush as the Enhanced Infusion System. PeriCoach obtained TGA, CE-mark and US FDA clearances, including US over-the-counter clearance in 2016. Despite this, revenue never scaled beyond a few hundred thousand dollars a year. By June 2022 the company had accumulated losses of about A$107.6 million. Its 2021 pivot to sovereign manufacturing in Maryborough and its China joint venture did not produce sustainable revenue. The company entered administration in June 2023 and was removed from the ASX in August 2023.


What the company did. In its own corporate description, Analytica designed, developed and supplied Class I and Class II medical devices. Its stated aim was to build shareholder value by commercially developing viable, profitable devices. Third-party profiles (MarketBeat, Pearler) describe it as supplying medical devices in Australia, China and the Middle East. Those profiles name the PeriCoach System as the lead product and the AutoStart Burette Infusion System as the second product line.

Business model. Analytica was a product-led medical-technology company. It generated revenue mainly from hardware sales of the PeriCoach device. Sales went through four channels: direct-to-consumer, clinician-referred sales, wholesale distributors (for example Current Technology, Inc. in the US from 2015), and from 2021 regional joint-venture and distribution partners in China and the Middle East. The app and web portal were bundled with the device. Accessible disclosures show no separately monetised subscription or SaaS revenue line.

Value-chain position. Analytica was a design owner and regulatory sponsor. It outsourced manufacturing, first to a Sydney contract manufacturer from about 2014 and to offshore providers during the R&D and regulatory phases. It decided in 2021 to bring manufacturing in-house in Maryborough, citing better control of the supply chain and regulatory compliance.

Customer types and end-markets.

Independent characterisation. Analytica is a textbook example of a single-product ASX micro-cap medtech that won regulatory approval but never achieved commercial adoption. It obtained approvals in all three major Western regulatory systems (TGA, CE, FDA 510(k) and OTC) and built a defensible patent estate. However, it never found a partner with distribution scale. The company had said publicly in 2016 that it was looking for a major multinational partner, and no such deal was ever announced. Repeated reliance on loans from the chairman, small placements and government grants left the company structurally undercapitalised. This is consistent with management's own admission, reported by Biotech Daily in 2017, that limited capital had been a long-running difficulty.

Strategy

Stated strategy themes.

  1. Prove the device, then partner (2015–2018). The 2015 annual report set two goals: prove PeriCoach clinically and commercially, then secure a multinational partner. The company built clinical evidence (post-approval trial, case studies, US early-adopter sites) and regulatory breadth (FDA OTC clearance) to reduce a partner's time to market.

  2. Data as a moat. The company promoted the PeriVault exercise database as a basis for next-generation products.

  3. Geographic expansion through partners (2021). It formed the China JV covering manufacturing, CFDA/NMPA Class II registration, and channels through hospitals, postpartum centres, pharmacy chains and online platforms. It also expanded Middle East distribution across ten nations.

  4. Sovereign/regional manufacturing (2021–2022). It planned to bring production in-house at Maryborough, citing supply-chain control, regulatory compliance, responsiveness to distributors, and the ability to restart direct-to-consumer sales and pursue health-system and insurer deals.

Initiatives in the final 24 months as a listed company (Aug 2021 – Aug 2023).

Medium-term financial targets / guidance. None published.

ESG / sustainability commitments. None published.

Products & Services

PeriCoach System (pelvic health)

AttributeDetail
DescriptionConnected pelvic-floor muscle trainer with biofeedback. It has three parts: (1) an intravaginal sensor device that measures pelvic-floor muscle activity; (2) a smartphone app that guides Kegel exercises with real-time feedback; (3) a cloud web portal through which clinicians monitor patient progress.
Data asset"PeriVault", which the company described as the world's largest pelvic-floor muscle exercise database
IndicationsStress urinary incontinence (primary). CE mark extended to pelvic organ prolapse. Postpartum rehabilitation and preventive senior-care positioning in China.
Target customersWomen with SUI (company claim: about 1 in 3 women have pelvic-floor problems), women's health physiotherapists, urogynaecologists, postpartum care centres, pharmacy chains
Regulatory statusTGA (Australia); CE mark (EU); US FDA clearance (March 2015) and OTC clearance (2016); planned registration as a Class II device with China's NMPA (formerly CFDA) through the JV (outcome not disclosed)
VersionsV1 commercial in November 2014; V2 (date not disclosed); V3 available from 1 May 2017
IPPatents in Australia, the US (including motion-sensor claims), China (2016), Europe and India
PricingNot publicly disclosed in accessible sources
Current statusBusiness sold to Stratos Medtech (2023). Stratos briefly held a Class I "Perineometer" ARTG entry (January–April 2024).

Enhanced Infusion System (EIS): AutoStart and AutoFlush

AttributeDetail
DescriptionTechnologies for intravenous infusion that monitor and automatically refill burettes. The project names were AutoStart and AutoFlush.
Target customersHospitals, especially paediatric and critical-care infusion settings where burettes are used
IPAutoStart burette patent granted (reported in the June 2016 quarter)
MarketsMiddle East expansion announced 31 March 2021 through Analytica Export ME Pty Ltd
Pricing / sales volumes—

Ancillary / adjacent offerings

OfferingDetail
Maryborough call centre and data centrePart of the 2021 facility plan, to support PeriCoach training, administration and data
Clinical evidence programmePost-approval clinical trial, published case studies, and early-adopter US clinic sites (2015–16)
SportsMed integration (2014 MoU)Planned access to women's sport and women-only gym markets. Non-binding; no conversion disclosed.

Financial Narrative

Disclosure limitation. Analytica's last complete reported financial year is FY2022 (to 30 June 2022). No FY2023 annual report was published before administration. That document gives FY2022 revenue, FY2021 and FY2022 net losses, accumulated losses and net tangible assets (NTA) per share. All other cells are blank by design.

Income statement (AUD)

Sources: FY2022 Appendix 4E (revenue, net losses, nil dividends). Market Index records no dividend history for ALT.

Margins and growth

The FY2022 net margin is calculated as -2,238,553 / 285,726. A 5-year revenue CAGR cannot be computed because FY2017–FY2021 revenue is not available from verifiable sources.

Interim datapoints (AUD)

Sources: Biotech Daily, 2 June 2017 (H1 FY2017); Stockhead and Kalkine (H1 FY2021: revenue up 7% to about A$81k, net loss about A$0.45M). The A$1.99M H1 FY2017 "revenue" very probably includes R&D Tax Incentive income rather than product sales, since quarterly customer receipts at the time were tens of thousands of dollars. Treat it with caution.

Balance sheet (AUD)

Source: FY2022 Appendix 4E, items 8 and 9. Accumulated losses also reflect transfers from the option reserve of A$810,569 in FY2022 and A$41,619 in FY2021.

Key solvency observation. NTA per share was negative in both FY2021 and FY2022. With roughly 4.6 billion shares on issue (the count implied by MarketBeat's A$4.61M market capitalisation at A$0.001), an NTA of -A$0.0005 per share implies a net tangible liability position of roughly A$2.3M at 30 June 2022. This is an analyst derivation. The DOCA disclosure that about A$3.1M was owed to entities associated with chairman Dr Michael Monsour confirms that related-party debt was the principal funding source by 2023. Eulerpool reports latest equity of -A$146,700, but that figure could not be reconciled with primary filings and is not relied on.

Cash flow and ratios

Historical burn reference: quarterly cash outflows were about A$888,000 in the March 2017 quarter, with an estimated quarterly burn of A$955,000 (Biotech Daily 2017). Cash was A$1.234M at 31 March 2017, excluding A$1.02M of placement proceeds received afterwards.

Ratios. ROE, ROA and ROIC are not meaningful because the company was loss-making with negative tangible equity. Current ratio, debt/equity, net debt/EBITDA, asset turnover and cash conversion cycle are not publicly disclosed in accessible sources. Interest coverage is negative.

Commentary

Analytica's financial history is one of persistent losses against negligible commercial revenue. Accumulated losses passed A$107 million by June 2022. That is extraordinary relative to the company's revenue base, and it reflects decades of development spending, including the pre-PeriCoach burette era. The FY2022 results contain three inflections. First, revenue fell 64% to A$285,726. That reversed whatever gains the 2021 China and Middle East announcements had produced, which suggests early JV and distributor stocking orders did not repeat. Second, the net loss rose 48% to A$2.24M as Maryborough manufacturing preparation and corporate costs increased. Third, tangible net worth deteriorated further. By 2023 the company relied on director loans, and voluntary administration followed within about ten months of the FY2022 report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipFunction (inferred from name and disclosures)

Analytica Limited

Parent; ASX-listed until Aug 2023

Holding company, IP owner, regulatory sponsor

PeriCoach Pty Ltd

100%

PeriCoach product entity. Its shares were sold to Stratos under the 2023 DOCA.

Analytica Operations Pty Ltd

100%

Operating and manufacturing entity (Maryborough strategy)

Analytica Export ME Pty Ltd

100%

Middle East export vehicle for the infusion system and PeriCoach distribution

Revenue by Segment (AUD)

SegmentFY2021FY2022

Medical devices, consolidated revenue (AUD)

—285,726

Medical devices, net loss after tax (AUD)

-1,507,406-2,238,553

Income Statement (AUD)

MetricFY2018FY2019FY2020FY2021FY2022

Revenue from ordinary activities (AUD)

————285,726

Net loss attributable to members (AUD)

———-1,507,406-2,238,553

Dividends per share (AUD)

00000

Margin Analysis (%)

MetricFY2022

Revenue growth YoY (%)

-64

Net loss growth YoY (%)

48

Net margin (%)

-783

Income Statement (AUD) (Half-Yearly)

MetricH1 FY2017 (Dec 2016 half)H1 FY2021 (Dec 2020 half)

Revenue (AUD)

1,990,00081,000

Net loss (AUD)

-938,700-450,000

Key Financials (AUD) and Per-Share Data

MetricFY2020FY2021FY2022

Accumulated losses at year end (AUD)

-104,726,230-106,192,017-107,620,001

Net tangible assets per share (AUD)

—-0.00045-0.0005

Financial Analysis

MetricFY2018FY2019FY2020FY2021FY2022

Dividends paid (AUD)

00000

Buybacks (AUD)

00000

Region Overview

RegionActivityPeriodEvidence

Australia

PeriCoach direct and clinician sales; TGA-registered; Queensland manufacturing plan

2014–2023

Company releases; Queensland Government

United States

FDA-cleared; launched 23 Jun 2015; Current Technology, Inc. distribution; Denver sales lead

2015–c.2018

BioSpace

United Kingdom / EU

CE mark; UK distribution agreements (2015–16)

2015–c.2018

Wholesale Investor

China, Macau, Hong Kong, Taiwan

JV with Hebei Nacol Bio-Technology and Shijiazhuang Biosphere

2021–2023

BioWorld; Stockhead

Middle East (ten nations)

Distribution of the infusion system and PeriCoach through Analytica Export ME

2021–2023

AuManufacturing; Owler log

Region

FY2020

FY2021

FY2022

Total revenue (AUD)

——285,726

Valuation Snapshot

MetricValueSource / date

Last traded price (AUD)

0.001

Biotech Daily, 25 Jul 2023

Last reference market cap (AUD Mn)

4.61

MarketBeat

Shares on issue (approx., M)

4,610

Implied by aggregator market cap at A$0.001

P/E

Not meaningful (losses)

—

EV/Sales

Not computable (net debt not disclosed)

—

Price/Sales (aggregator TTM)

14.47

iocharts

P/B

Not meaningful (negative tangible equity)

—

Share Price & Returns

PeriodAnnualised return (%)

3-year

-26.32

5-year

-30.12

10-year

-25.74

Share Price and Market Valuation

Metric201720212023

Share price (AUD)

0.0050.0020.001

Market cap (AUD Mn)

13—4.61

Shares on issue (M)

2,549—4,610

Capital Markets

ItemStatus

Analyst consensus

None (no broker coverage identified)

Dividend history / policy

No dividends ever paid

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Not publicly disclosed. Debt consisted mainly of director/related-party loans (about A$3.1M of chair-associated claims at the DOCA).

Listed options

ALTOB, expired 18 June 2023

Analyst Conclusions

Management guidance. None. The company is delisted, its business has been sold, and the listed shell was slated for solvent winding-up.

Consensus growth expectations. None. There is no coverage.

Bull-case arguments (for the PeriCoach asset under private ownership)

  1. The technology is validated. FDA (including OTC), CE and TGA clearances and multi-jurisdiction patents mean that Stratos acquired a regulatory-ready, IP-protected device for a very small consideration (A$290k deed fund).

  2. The structural market need is real. About 1 in 3 women have pelvic-floor problems, and there is a roughly US$7B US pad market to substitute into. Femtech capital flows support the category.

  3. Clean-slate economics. Stripped of listed-company costs and A$107M of historic losses, a lean private operator in Maryborough could run PeriCoach as a profitable niche business.

Bear-case arguments

  1. A decade of commercial failure. Revenue never went above a few hundred thousand dollars a year from product sales, and it fell 64% in FY2022 even after the China and Middle East deals.

  2. Competitive displacement. Better-funded consumer brands such as Elvie and Perifit now dominate attention in connected pelvic-floor training.

  3. Successor status is uncertain. Stratos's Class I ARTG entry was cancelled within three months (April 2024), and no subsequent commercial activity has been verified.

Key catalysts and monitorables (next 12 months)

  • Completion records for the winding-up of Analytica Limited (ASIC registry status).

  • Any Stratos Medtech TGA, FDA or NMPA registrations or relaunch of PeriCoach.

  • The status of Queensland AQIAF grant repayment obligations, if milestones were missed.

  • Any activity from the China JV (Hebei Nacol) involving PeriCoach.

  • Clarification of the post-2023 ALT code usage reported by data aggregators.

Concluding analyst verdict

Analytica Limited no longer exists as an investable listed security, and for public-equity purposes the investment case is closed. Ordinary shareholders lost effectively all of their value. The shares last traded at 0.1 cents, and the operating business was sold under a DOCA that funded only A$290,000 for administrator costs and creditor claims. About A$3.1 million of those claims belonged to entities associated with the chairman. The outcome caps a 23-year listed history. By June 2022 that history had produced roughly A$107.6 million of accumulated losses, against annual revenue that peaked in the hundreds of thousands of dollars and fell to A$285,726 in the company's final full year.

The company's failure was not mainly technological. PeriCoach was a credible, well-regulated, patented product that reached market early, cleared the FDA's over-the-counter bar and attracted distinguished directors. The failure was commercial and financial. Analytica could never fund the consumer marketing that femtech adoption requires, never secured the multinational partner it publicly sought from 2015, and spent its final two listed years on a capital-intensive manufacturing pivot that depended on government grants and that the balance sheet could not support. Concentrated insider funding kept the company alive but also shaped its endgame: a sale to newly formed buyers in the chairman's home town, with control of the shell returning to the directors.

For analysts, the case is a useful reference for ASX micro-cap medtech. Regulatory approval is not commercial validation. Sub-cent capital raising compounds dilution without building scale. Related-party lenders ultimately decide how an insolvency is resolved. Any residual interest now lies only in monitoring whether Stratos Medtech can commercialise PeriCoach privately. Early signals, including the cancelled 2024 ARTG entry, are not encouraging. Verdict: Delisted, no equity value; monitor the successor asset only.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / notesSource

Dr Michael Monsour

Chairman

Chairman from at least 2014 to 2023. Lives in Maryborough. Largest shareholder (22% in 2017). His associated entities were owed about A$3.1M at the DOCA.

Biotech Daily 2017, 2023

Geoff Daly

CEO; earlier Operations Manager (2014)

CEO c.2015–2023.

Australian Manufacturing; Stockopedia

Ross Mangelsdorf

Director; CFO (per aggregator)

Director from at least 2017; held 2.4% (2017)

Biotech Daily 2017; Datanyze

Warren Brooks

Non-executive director

Board member as of 2017

Biotech Daily 2017

Carl Stubbings

Non-executive director

Board member as of 2017

Biotech Daily 2017

Dr Thomas Lönngren

Non-executive director

Board member as of 2017; former Executive Director of the European Medicines Agency (public record)

Biotech Daily 2017

Dr Peter Corr

Non-executive director

Board member as of 2017; 13% holder (2017); former senior Pfizer R&D executive (public record)

Biotech Daily 2017

Megan Henken

VP Global Sales & Marketing (Denver)

c. 2015

BioSpace

Major Shareholders

HolderStakeAs at

Dr Michael Monsour (and associates)

22%2,017

Dr Peter Corr

13%2,017

Ross Mangelsdorf

2.4%2,017

Institutional holders

Not publicly disclosed; likely negligible given micro-cap status

—

Competitive Landscape

Competitors by Segment

SegmentCompetitorProductOwnership

Connected pelvic-floor trainers

Chiaro Technology Ltd (UK)

Elvie Trainer

Private

Connected pelvic-floor trainers

X6 Innovations (France)

Perifit

Private

Connected pelvic-floor trainers

Minna Life (US)

kGoal

Private

Pelvic-floor stimulation

InControl Medical (US)

InTone / Attain

Private

Prescription pelvic-floor devices

Axena Health (formerly Renovia, US)

leva

Private

Clinic-based pelvic-floor therapy

BTL Industries

Emsella chair

Private

Clinical biofeedback / urodynamics

Laborie Medical Technologies

Pelvic-floor biofeedback systems

Private (PE-owned)

Continence pads (substitute)

Essity (TENA), Kimberly-Clark (Poise)

Absorbent products

Listed large-caps

IV infusion sets / burettes

B. Braun; Baxter; ICU Medical

Burette and infusion sets

Private / listed large-caps

China pelvic rehabilitation

Domestic Chinese electro-stimulation and biofeedback makers

Postpartum rehabilitation devices

Various

Competitor Detail

MetricAnalytica (FY2022)

Revenue

A$285,726

Revenue growth

-64%

Net margin

About -783%

Regulatory

TGA, CE, FDA (OTC)

Recent Developments

The company stopped publishing disclosures in mid-2023, so an 18-month window from today has no company newsflow.

Discrepancy flag: * Market Index lists "Final/Estimated Distribution Announcement" notices dated 1 July 2024, 9 October 2024 and 1 July 2025 under the code ALT, labelled "Analytica Limited, Healthcare". These postdate Analytica's removal from the Official List. They are most likely a ticker-code reassignment or a data-provider mapping error, not Analytica disclosures. They are excluded from this analysis.

Company Snapshot

1985

Founded

Brisbane, Australia

Headquarters

SWOT Analysis

Strengths

  • Regulatory breadth: FDA clearance in March 2015 and OTC clearance in 2016, plus CE mark and TGA registration.
  • Indication expansion: CE mark extended to pelvic organ prolapse.
  • Granted IP: patents in China (2016), the US (including motion sensors), Europe, India, and AutoStart (2016).
  • Data asset: PeriVault, which the company promoted as the largest pelvic-floor exercise database.
  • Product iteration: three device generations; V3 available from 1 May 2017.
  • Government backing: a Queensland AQIAF-supported A$13.8M facility plan (2021) and a federal A$4.8M commitment (2022).

Weaknesses

  • Negligible revenue: A$285,726 in FY2022, down 64%.
  • Chronic losses: accumulated losses of A$107.6M by 30 June 2022.
  • Negative tangible equity: NTA of -A$0.0005 per share (FY2022).
  • Related-party funding dependence: about A$3.1M owed to chairman-associated entities at administration.
  • Poor commercial efficiency: A$714k quarterly marketing spend against A$47k of receipts (December 2015 quarter).
  • Heavy dilution: about 2.55B shares (2017) rising to about 4.6B (2023 implied).

Opportunities

  • China JV: potential NMPA Class II prescription listing in hospitals and postpartum centres.
  • Middle East: ten-nation distribution for the infusion system and PeriCoach.
  • Payer channels: health insurers and public health systems (2021 strategy).
  • Direct-to-consumer restart: enabled by in-house manufacturing.
  • Large addressable market: about US$7B US pad market as a substitution target.
  • Femtech investor interest: venture funding flowing to pelvic-health peers.

Threats

  • Well-funded private competitors: Elvie, Perifit and others.
  • Grant conditionality: the AQIAF grant was repayable if milestones were missed.
  • Going-concern and insolvency risk: this materialised on 13 June 2023.
  • Execution risk on the China JV: a partner-dependent model with no disclosed revenue.
  • Listing compliance risk: materialised with removal for unpaid fees in August 2023.
  • Minority-shareholder value destruction: last traded at 0.1 cents; business sold for a A$290k deed fund.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
H1 FY2021 (Dec 2020 half)Revenue up 7% to about A$81k; net loss about A$0.45MCommercial base remained tiny
FY2020–21JobKeeper payments notificationCOVID wage-subsidy support
FY2020–21Additional US patent granted for PeriCoachIP strengthening
30 Mar 2021China JV announced; share price up about 100% on the dayLargest positive catalyst in years
31 Mar 2021Enhanced Infusion System expanded into the Middle EastRevived the legacy product line
27 Apr 2021Plan to manufacture in MaryboroughStrategic pivot to in-house production
22 Jun 2021 (approx.)Chairman disclosed Maryborough residency in coverageContext for the location choice
6 Sep 2021Manufacturing strategy update; Queensland grant (amount not disclosed; milestone-based)Funding for the pivot
6 Sep 2021Shares unchanged at 0.2 cents on 25.0M shares tradedMuted market reaction
16 Sep 2021Queensland Government: A$13.8M facility, up to 194 jobsPolitical backing
16 Sep 2021Appendix 4D half-year audit-reviewed reportPeriodic filing
2021–22Listed options issued (ALTOB, expiring 18 Jun 2023); cleansing prospectus; results of meeting; substantial-holding changesCapital management
2022Federal A$4.8M commitment for Maryborough productionFurther political support
31 Aug 2022FY2022 Appendix 4E: revenue A$285,726 (-64%); loss A$2.24M (+48%)Deteriorating fundamentals
31 Aug 2022FY2022 annual report and corporate governance statementLast complete annual disclosure
2022–23Advanced discussions with directors over loansLiquidity stress
2022–23CEO Geoff Daly resignedLeadership gap
13 Jun 2023Voluntary administrators (David Clout & Associates) appointedInsolvency event
13 Jun 2023Stratos Medtech Pty Ltd incorporated (Maryborough)Buyer vehicle formed
Jun 2023Administrators sought expressions of interest for the sale of AnalyticaSale process
18 Jun 2023ALTOB options expiredCapital structure simplified
26 Jun 2023Stratos Medtech Holdings Pty Ltd incorporatedBuyer holding vehicle
24 Jul 2023Creditors approved the DOCA with Stratos (A$290k deed fund)Business sold
25 Jul 2023Shares in suspension; last traded at 0.1 centsEquity value effectively nil
22 Aug 2023ASX suspension for unpaid annual listing feesListing lapse
29 Aug 2023Removal from the ASX Official ListEnd of public company status
29 Jan 2024Stratos MedTech ARTG entry for a Class I PerineometerSuccessor re-registration attempt
23 Apr 2024ARTG entry cancelled at the sponsor's requestSuccessor commercial status uncertain

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (AUD): Medical devices, consolidated revenue was AUD 285,726 in FY2022.
Analytica Limited — Revenue by Segment (AUD)
Series (AUD)FY2021FY2022
Medical devices, consolidated revenue—285,726
Medical devices, net loss after tax-1,507,406-2,238,553

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Analytica Limited, Appendix 4E and Annual Report FY2022 (31 Aug 2022), via (aspecthuntley.com.au)
  2. ASX Market Announcement, "Suspension from Official Quotation", 22 Aug 2023 (announcements.asx.com.au)
  3. InvestSMART ALT announcement log (Removal from Official List, 29 Aug 2023) (investsmart.com.au)
  4. Biotech Daily, 25 Jul 2023 (DOCA with Stratos Medtech) (biotechdaily.com.au)
  5. Biotech Daily, 2 Jun 2017 (Dr Boreham's Crucible: Analytica) (biotechdaily.com.au)
  6. Biotech Daily, 6 Sep 2021 (Queensland grants) (biotechdaily.com.au)
  7. Queensland Ministerial Statement, 16 Sep 2021 (statements.qld.gov.au)
  8. AuManufacturing, Maryborough factory report (aumanufacturing.com.au)
  9. Llew O'Brien MP, A$4.8M Maryborough commitment (llewobrien.com.au)
  10. BioWorld, "Analytica expands into China with JV" (2 Apr 2021)
  11. Stockhead, PeriCoach China JV report (stockhead.com.au)
  12. BioSpace, Current Technology US distribution release
  13. Wholesale Investor, Analytica Appendix 4C/4D summaries (2016)
  14. Australian Manufacturing, first PeriCoach production run (2014)
  15. Finance News Network, SportsMed MoU (13 Oct 2014)
  16. TGA ARTG 438491 and Stratos MedTech sponsor page (tga.gov.au)
  17. Market Index ALT page (marketindex.com.au)
  18. MarketBeat ALT page; Pearler ALT/ALTOB pages; iocharts ALT.AU; Kalkine (16 Jul 2021); Owler; Datanyze; Stockopedia (aggregators)
  19. Eulerpool (equity and interest-coverage figures noted but not relied on because they could not be reconciled with primary filings)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.